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The purpose of this study was to analyze the antigenic structure of the nucleocapsid protein N of the Lelystad virus isolate
of porcine reproductive and respiratory syndrome virus (PRRSV) and to identify antigenic differences between this prototype
European isolate and other North American isolates. To do this, we generated a panel of monoclonal antibodies (mAbs)
directed against the N protein of Lelystad virus and tested them in competition assays with other N-specific mAbs described
previously (Drew et al., 1995; Nelson et al., 1993; van Nieuwstadt et al., 1996). Four different competition groups of mAbs were
identified. Pepscan analysis with solid-phase dodecapeptides was used to identify specific antigenic regions in the N protein
that were bound by the mAbs. In this pepscan analysis, we found that the mAb of the first competition group reacted with
linear peptides whose core sequences consisted of amino acids 2–12 (site A), the mAbs of the second group reacted with
peptides whose core sequences consisted of amino acids 25–30 (site B), and the mAb of the third group reacted with
peptides whose core sequences consisted of amino acids 40–46 (site C). However, the fourth group of mAbs binding to an
antigenic region, provisionally designated as domain D, reacted very weakly or did not react at all with solid-phase
dodecapeptides.To further characterize the structure of the epitopes in domain D, we produced chimeric constructs
composed of the N protein sequences of Lelystad virus and another arterivirus lactate dehydrogenase-elevating virus, which
was used because its N protein has similarity in amino acid sequence and hydropathicity profile but does not react with our
mAbs. When the mAbs specific to domain D were tested for binding to the chimeric N proteins expressed by Semliki Forest
virus, we found that the regions between amino acids 51–67 and amino acids 80–90 are involved in the formation or are part
of the epitopes in domain D. Therefore, we conclude that the N protein contains four distinct antigenic regions. The epitopes
mapped to sites A–C are linear, whereas the epitopes mapped to domain D are more conformation dependent or
discontinuous. Sites A and C contain epitopes that are conserved in European but not in North American isolates; site B
contains epitopes that are conserved in European and North American isolates; and site D contains epitopes that are either
conserved or not conserved in European and North American isolates. The antigenic regions identified here might be
important for the development of diagnostic test for PRRSV in particular tests that discriminate between different antigenic
types of PRRSV. © 1998 Academic Press
INTRODUCTION
Porcine reproductive and respiratory syndrome virus
(PRRSV) belongs to the family of arteriviruses together
with equine arteritis virus (EAV), lactate dehydrogenase-
elevating virus (LDV), and simian hemorrhagic fever virus
(Meulenberg et al., 1993; Plagemann and Moennig, 1992).
It causes abortions in pregnant sows and respiratory
distress in piglets (Wensvoort et al., 1991; Collins et al.,
1992), and it causes huge economic losses worldwide.
Infection most frequently occurs by the respiratory route,
and virus replication in the respiratory tract is followed
by viremia and dissemination throughout the body. The
genome of PRRSV is 15 kb in length and contains genes
encoding the RNA-dependent RNA polymerase (ORF1a
and ORF1b) and genes encoding structural proteins
(ORFs 2–7; Meulenberg et al., 1993). ORF5 encodes the
major envelope glycoprotein, designated GP5 (Mardassi
et al., 1996; Meulenberg et al., 1995b). The ORFs 2–4
encode glycoproteins designated GP2, GP3, and GP4,
respectively. These glycoproteins are less abundantly
present in purified virions of the Lelystad virus (LV) iso-
late of PRRSV (Meulenberg et al., 1996; Van Nieuwstadt
et al., 1996). The GP5 protein forms a disulfide-linked
heterodimer with the membrane protein M encoded by
ORF6 (Mardassi et al., 1996). The nucleocapsid protein N
is encoded by ORF7 (Mardassi et al., 1996; Meulenberg
et al., 1996). The analysis of the genome sequence of
PRRSV isolates from Europe and North America and their
reactivity with monoclonal antibodies (mAbs) has proved
that they represent two different antigenic types. The
isolates from these continents are genetically distinct
and must have diverged from a common ancestor rela-
tively long ago (Kapur et al., 1997; Murtaugh et al., 1995).
Many studies have shown that the N protein is the most
antigenic protein of PRRSV. For example, pigs infected with
PRRSV develop strong antibody responses against the N
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protein (Loumba et al., 1996; Meulenberg et al., 1995a; Sanz
et al., 1995). Furthermore, most mAbs produced from mice
that were immunized with (partially) purified virions of
PRRSV were directed against the N protein (Drew et al.,
1995; Nelson et al., 1993; Rodriquez et al., 1997; van
Nieuwstadt et al., 1996). Therefore, it was suggested to be
a useful antigen for the development of routine diagnostic
tests to detect serum antibodies against PRRSV (Denac et
al., 1997; Meulenberg et al., 1995a; Rodriquez et al., 1997).
For the design of these tests, it is important to know the
antigenic structure of the N protein, in particular the simi-
larities and differences between European and North
American isolates of PRRSV. The ability to differentiate
between these isolates is becoming critical because vac-
cine virus of the North American antigenic type has recently
been introduced into Europe.
Thus although the antigenic importance of the N protein
is widely recognized, little has been known until now about
the antigenic structure of the N protein or to what extent the
N proteins of the North American and European isolates
differ antigenically. The purpose of this study was to identify
the antigenic regions of the N protein using a variety of
mAbs from various laboratories. Some of the mAbs recog-
nized only the N protein of European isolates, whereas
others recognized the N protein of both European and
North American isolates. We used the mAbs in competition
assays to analyze whether they bound similar or distinct
antigenic regions on the N protein. Pepscan analysis was
used to more precisely map the binding sites of the mAbs.
The binding sites of the mAbs that did not react in pepscan
analysis were further characterized in studies with chimeric
N proteins. With these methods, four antigenic regions
were identified: three antigenic sites contained linear
epitopes, and one antigenic domain contained conforma-
tion-dependent or discontinuous epitopes.
RESULTS
Production and specificity of mAbs recognizing the N
protein
In a previous report, we described the isolation of two
mAbs (122.17 and 126.9) that reacted with the N protein of
LV and other European and North American isolates of
PRRSV (van Nieuwstadt et al., 1996). Besides these two
mAbs, seven other N protein-specific mAbs were devel-
oped (Table 2). mAbs 125.1, 130.2, 130.4, 131.7, and 131.9
recognized epitopes on the N protein that are conserved
in both European and North American isolates of PRRSV,
whereas mAbs 138.22 and 126.15 recognized an epitope
that is conserved in European isolates but not in North
American isolates (Table 2). The whole panel of N-spe-
cific mAbs reacted with the N protein of LV in the immu-
noperoxidase monolayer assay (IPMA), immunoprecipi-
tation assay, Western blots, and ELISA and did not neu-
tralize the virus.
TABLE 1
Properties of mAbs that Bind to the N Protein and Were Used in This Study
mAb Isotype
Titer in IPMAa
with LV
Reaction with
US isolatesb
Binding to
antigenic region Pepscan on N protein of LVc
138.22 IgG1 25 2 A 1-MAGKNQSQKKKKS-13
125.1 IgG1 250 1 B 19-NGQPVNQLCQLLGAMIKS-36
126.9 IgG2b 250 1 B 19-NGQPVNQLCQLLGAMIKSQ-37
NS95 IgG1 NAd 1 B 19-NGQPVNQLCQLLGAMIKS-36
NS99 IgG1 NAd 1 B 19-NGQPVNQLCQLLGAMIKSQ-37
126.15 IgG1 250 2 C 35-KSQRQQPRGGQAKKKKP-51
122.17 IgG1 2000 1 D 6e
130.2 IgG1 250 1 D 6e
130.4 IgG1 250 1 D 6e
131.7 IgG1 250 1 D 6e
131.9 IgG1 250 1 D 6e
SDOW17 IgG1 250 1 D 6e
WBE1 IgG2a 1000 2 D 6e
WBE4 IgG1 1000 2 D 6e
WBE5 IgG1 2000 2 D 2
WBE6 IgG1 1000 2 D 2
a Reciprocal of the highest dilution of HRPO-conjugated mAb (4 mg IgG/ml) positive in an indirect immunoperoxidase monolayer assay of lung
alveolar macrophages infected with LV. Similar titers were obtained using other European isolates of PRRSV.
b Reactivity in IPMA with 10 U.S. isolates from different states, which were characterized previously (Kapur et al., 1997).
c The core amino acid sequence of the peptides, reacting with the mAbs is indicated.
d NA 5 not available.
e 6 indicates that binding of the mAb was observed but was batch dependent or did not fulfill the criterion for being above background (see
Results).
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Identification of four competition groups of mAbs
The ability of the mAbs to block the binding of another
mAb that was conjugated with horseradish peroxidase
(HRPO) was assessed in IPMA with LV-infected macro-
phages. Besides the nine mAbs isolated in our labora-
tory, four N-specific mAbs raised against a U.K. isolate of
PRRSV (WBE1, WBE4, WBE5, and WBE6; Drew et al.,
1995), one N-specific mAb raised against U.S. isolate
VR2332 (SDOW17; Nelson et al., 1993) and two N-specific
mAbs raised against the LV isolate (NS95 and NS99;
Nelson et al., 1996) were tested. Four distinct antigenic
sites were identified (Fig. 1). HRPO-conjugated mAbs
138.22 and 126.15 were blocked only by their homolo-
gous native mAbs, suggesting that they recognize two
distinct epitopes at sites that were designated A and C,
respectively. Sites A and C are specific for the N protein
of European PRRSV isolates because mAbs 138.22 and
126.15 do not recognize North American PRRSV isolates
(Table 2). HRPO-conjugated mAbs 126.9 and 125.1 were
blocked by their homologous native mAbs and recipro-
cally by each other, indicating that they bind to adjacent
or overlapping epitopes located at a distinct site, desig-
nated B. mAbs NS95 and NS99, which were available
only in their native form, also blocked the binding of
mAbs 126.9 and 125.1, indicating that they bind to site B
as well. Site B is probably conserved in European and
North American PRRSV isolates because mAbs 126.9,
125.1, NS95, and NS99 recognize PRRSV isolates from
both continents.
Interestingly, the fourth and largest group of mAbs that
competed mainly reciprocally with each other for binding
of the N protein consisted of mAbs that recognize both
European and North American isolates of PRRSV (122.17,
130.2, 130.4, 131.7, 131.9, and SDOW17) and mAbs that
recognize European isolates only (WBE1, WBE4, WBE5,
and WBE6). Within this group, nonreciprocal blocking
was observed (Fig. 1). Whereas reciprocal competition of
mAbs indicates that their epitopes overlap or are adja-
cent on the antigen, nonreciprocal competition may be
explained in several ways. The affinity of the two mAbs
may differ greatly; the binding of one mAb may induce a
change in conformation that alters the binding of the
other mAb; the binding of one mAb may sterically hinder
the binding of the other mAb; or conjugating one mAb to
peroxidase may alter the ability of the mAb to bind.
Therefore, the information gained from nonreciprocal
FIG. 2. Pepscan analysis of mAbs on overlapping 12-mer peptides
covering residues 1–128 of the N protein. The scans of mAbs 138.22,
126.9, and 126.15 are shown in a, b, and c, respectively. These scans
are representative for the mAbs directed to sites A–C, respectively, as
discussed under Results and shown in Table 2.
FIG. 1. Epitope mapping by competitive binding in IPMA. Macrophages were seeded onto M96 wells and infected with LV. At 24 h after infection,
cells were fixed and incubated with the nonconjugated and HRPO-conjugated mAbs as described under Materials and Methods. The highest dilution
of the nonconjugated mAb completely blocking the binding of the conjugated mAb is indicated. The four distinct antigenic regions (A–D) bound
specifically by the mAbs are indicated.
108 MEULENBERG ET AL.
competition is not straightforward. Nevertheless, the
data suggest that the epitopes of mAbs 122.17, 130.2,
130.4, 131.7, 131.9, WBE4, WBE5, and WBE6 are adjacent
or partially overlapping within one antigenic domain,
provisionally designated D. Even though the picture for
SDOW17 and WBE1 was less clear, their binding sites
also seem to be in close proximity to domain D.
Fine mapping of three linear antigenic sites in the N
protein by pepscan analysis
When the fine specificity of the mAbs was further
investigated with synthetic peptides (12 mers) from the N
protein in pepscan analysis, 6 of the 16 mAbs reacted
positively (Fig. 2, Table 2). mAb 138.22 reacted to two
consecutive overlapping peptides covering amino acids
1–13, with the sequence AGKNQSQKKKK (site A) as core.
mAbs 125.1, 126.9, NS95, and NS99 reacted with peptides
covering amino acids 19–37, with the sequence QLCQLL
as core (site B). mAb 126.15 reacted with peptides cov-
ering amino acids 35–51, with the sequence QPRGGQA
as core (site C). The three distinct linear binding sites
identified for these mAbs are in agreement with the
results of blocking experiments described above and
with their reactivity with North American isolates. The
amino acid sequence of sites A and C defined by mAbs
138.22 and 126.15, which bind only European isolates of
PRRSV, is very different in the N protein of VR2332 (Fig. 3)
and other North American isolates (Kapur et al.,1997). In
contrast, the amino acid sequence of site B, defined by
mAbs 125.1, 126.9, NS95, and NS99, which bind both
European and North American isolates, is conserved in
the N protein sequence of PRRSV isolates from both
continents (Fig. 3).
The mAbs specific for domain D could not be mapped
with certainty due to too low reactivity above background
to be regarded as antigenic or a variable reactivity be-
tween batches, or both. mAbs 130.2, 130.4, 131.7, 131.9,
WBE1, and WBE5 reacted very weakly with peptides
covering amino acids 50–74, whereas mAb SDOW17
reacted very weakly with peptides covering amino acids
20–37 (data not shown). Because of the good reactivity in
other immunochemical tests with recombinant protein
and virus (Tables 2 and 3), the epitope of each of these
mAbs is probably discontinuous or dependent on the
conformation of the N protein. mAbs 122.17 and 130.2
exhibited low affinity to more than one stretch of amino
acids between residues 19–36 and 50–74 (data not
shown). Binding of mAbs to more than one stretch of
amino acids in pepscan has been observed before and
is additional evidence that the epitope is discontinuous
(Posthumus et al., 1990; Korth et al., 1997).
Analysis of the epitopes in domain D using chimeric
N proteins
In our first attempt to map domain D, various deletions
were made at the 39 end of ORF7, resulting in truncated
N proteins that lacked amino acids at the C terminus.
These truncated N proteins were expressed by Semliki
Forest virus in BHK-21 cells and stained in IPMA with the
N-specific mAbs. However, the N protein with the small-
est deletion of 31 N-terminal amino acids was not
stained by the D-specific mAbs and was only very weakly
stained by the mAbs mapped to sites A–C. Thus the
C-terminus of the N protein appeared to be important for
its conformation, stability, or both (data not shown).
FIG. 3. Location of antigenic binding sites in the N protein sequence of LV and comparison of this N protein sequence with those of North American
strain VR2332 and LDV. Sites A–C and domain D are shown in shadow. The amino acid sequences of LV that were substituted for the corresponding
amino acid sequences of LDV to map domain D are underlined. The amino acids of the N protein of EAV that were inserted between amino acids
25–30 to mutate site B are shown underlined below the LDV sequence. Identical amino acids are connected with vertical bars.
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Consequently, we further mapped domain D with con-
structs of ORF7 expressing chimeric N proteins, thereby
keeping the conformation of the N protein as native as
possible. Because the D-specific mAbs produced in our
laboratory recognized both European and North Ameri-
can isolates of PRRSV, the regions that were most con-
served between the N protein of LV and the North Amer-
ican prototype VR2332 were mutated. The nucleotide
sequence coding for amino acids 51–67, 80–90, and
111–128 was substituted for a sequence that codes for
the corresponding amino acids of LDV (Fig. 3). For com-
pletion, site B (amino acids 25–30), which is also con-
served in European and North American isolates, was
mutated. Because the amino acid sequence of the N
protein of LV was very similar to that of the N protein of
LDV in site B, this region was substituted for a region
encoding the corresponding amino acids of the N protein
of EAV (Fig. 3). When the mutated and wild-type N pro-
teins were expressed in BHK-21 cells using the Semliki
Forest virus expression system and were tested with the
N-specific mAbs in IPMA, the D-specific mAbs reacted
identically (Table 3). Their binding was disrupted by mu-
tations between amino acids 51–67 and 80–90 but not by
mutations between amino acids 111–128 or amino acids
25–30 (site B). As expected, the N proteins with LDV
sequences between amino acids 51–67 and 80–90 were
still stained by mAbs directed against sites A–C. How-
ever, fewer cells were stained, and the brightness of the
staining was less than that observed for the wild-type N
protein and the N proteins mutated in amino acids 25–30
(site B) or amino acids 111–128 (Fig. 4). This was most
likely caused by a lower expression of the N proteins
containing mutations between amino acids 51–67 or
80–90 because a lower yield of these mutant N proteins
compared with the other N proteins was also obtained
when equal amounts of transcripts were translated in
vitro (data not shown). As expected, the N protein that
contained EAV sequences in site B was not recognized
by mAbs mapped to site B (by pepscan analysis) but was
still recognized by mAbs that mapped to sites A or C or
domain D. These data indicate that amino acids 51–67
and 80–90 are participating to form the conformation-
dependent or discontinuous epitopes mapped to domain D.
DISCUSSION
In this work, we identified four distinct antigenic re-
gions in the N protein of PRRSV. Three sites, designated
A–C, contain linear epitopes, and these were mapped
between amino acids 2–12, 25–30, and 40–46, respec-
tively. However, the fourth region, designated domain D,
contains conformation-dependent or discontinuous
epitopes that are (partially) composed of amino acids
51–67 and 80–90. Interestingly, not only mAbs produced
against the LV isolate of PRRSV (122.17, 130.2, 130.4,
131.7, and 131.9) but also mAbs produced against the H2
U.K. isolate (WBE1, WBE4, WBE5, and WBE6) and against
the North American isolate VR2332 (SDOW17) bound to
domain D. It is remarkable that immunization of mice
with LV resulted in the production of D-specific mAbs
that recognized both European and North American iso-
lates, whereas immunization of mice with the closely
related H2 U.K. isolate resulted in D-specific mAbs that
recognized European strains only, except for WBE1,
which recognized certain Canadian isolates (Le Gall et
al., 1997). We do not have an explanation for these
results. Within the group of mAbs specific for domain D,
some inconsistent reactions were observed in competi-
tive binding assays using SDOW17 and WBE1. Drew et
al. (1995) concluded that WBE1, SDOW17, and WBE4–6
probably bind to different regions in the N protein. A
distinct antigenic site for SDOW17 is in line with the
observation that SDOW17 does recognize North Ameri-
can isolates of PRRSV, whereas WBE1, WBE4, WBE5, and
WBE6 do not. However, in our study, when we mutated
two conserved regions of the N protein (amino acids
51–67 and 80–90), not only was the binding of mAbs
122.17, 130.2, 130.4, 131.7, 131.9, and SDOW17 that recog-
nize the N protein of European and North American
isolates disrupted, but also the binding of mAbs WBE1,
WBE4, WBE5, and WBE6 that recognize only European
isolates was disrupted. Apparently, the introduction of
mutations between amino acids 51–67 and 80–90 also
induces changes in the epitopes recognized by WBE1,
WBE4, WBE5, and WBE6 that may consist (partially) of
nonconserved amino acids present at positions 60 and
64 and other nonconserved residues in flanking regions
TABLE 2
Staining of Chimeric N Proteins Expressed by Semliki Forest Virus in BHK-21 Cells in IPMA
Plasmid Mutation
Staining with mAbs in IPMA
138.22
A
125.1/126.9/NS95/NS99
B
126.15
C
122.17/130.2/130.4/131.7/131.9/SDOW17/WBE1/WBE4/WBE5/WBE6
D
pABV470 2 111 111 11 111
pABV462 25–30 111 2 11 111
pABV518 51–67 11 11 1 2
pABV460 80–90 11 11 1 2
pABV471 111–124 111 111 11 111
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FIG. 4. Immunoperoxidase staining of BHK-21 cells transfected with RNAs from recombinant SFV constructs expressing chimeric and wild-type N
proteins. BHK-21 cells were transfected with transcripts from pABV470, pAB462, pABV518, pABV460, and pABV471 and mock transfected (2). At 24 h
after tranfection, cells were stained with mAbs 138.22 (site A), 126.9 (site B), and 122.17 (domain D) in IPMA.
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(Fig. 3). The fact that a C-terminal deletion of 31 amino
acids completely destroyed the binding of all D-specific
mAbs (data not shown) further confirmed that the con-
formation of the N protein is important for the binding of
these mAbs. Further mutagenesis of individual residues
between amino acids 51–90 is needed to determine
which residues are essential for the specific binding of
the different mAbs to the N protein. Recently, Nelson et
al. (1997) described a vaccine strain PrimePac PRRS
virus that had lost its reactivity with mAb SDOW17 during
serial passage in cell culture. This loss was caused by a
single amino acid change at position 61 (Asp to Tyr) in
domain D, a finding that agrees with our results. Further-
more, Le Gall et al. (1997) showed that mAb WBE1
recognized certain Canadian strains and therefore se-
quence analysis of the ORF7 gene of these isolates
might determine which amino acids are important for
binding of WBE1.
Because the majority of mAbs raised against different
PRRSV strains mapped to domain D, this region seems
to be an immunodominant region, at least in mice. Ro-
driquez et al. (1997) also found that three of the seven
mAbs produced against a Spanish isolate of PRRSV
were directed against domain D of the N protein. How-
ever, in contrast to the mAbs investigated here, their
mAbs were recognizing a linear peptide consisting of
amino acids 50–66.
Preliminary results have indicated that porcine sera
containing antibodies directed against both European
and North American PRRSV isolates can interfere with
the binding of D-specific mAbs in a blocking ELISA or
complex-trapping binding ELISA in which a recombinant
N protein product is used (Meulenberg et al., 1995a,
unpublished results). Therefore, the D-specific mAbs and
perhaps also the B-specific mAbs directed at conserved
regions of the N protein are valuable for developing a
diagnostic test to detect serum antibodies against
PRRSV isolates in pigs worldwide. We are currently in-
vestigating whether mAbs that bind to sites A and C
might also be used for the development of a diagnostic
test discriminating between European and North Amer-
ican isolates or vaccine strains based on these antigenic
types. This might be successful because sequence anal-
ysis (Kapur et al., 1996; Suarez et al., 1996) and typing of
different isolates with our A- and C-specific mAbs (de
Kluyver et al., 1995; current study) have shown that sites
A and C are conserved in European isolates but different
in North American isolates. In addition, site B and do-
main D are interesting regions to mutate in the recently
established infectious clone of LV (Meulenberg et al.,
1998) and to create viruses that can be serologically
differentiated from field virus and therefore may be prom-
ising mutants for marker vaccine development against
PRRSV.
MATERIALS AND METHODS
Cells and viruses
The European prototype Ter Huurne strain of LV was
isolated in 1991 (Wensvoort et al., 1991). The North Amer-
ican prototype VR2332 strain was isolated in 1992 by
Collins et al. (1992). LV and VR2332 were grown on
CL2621 cells as described previously (Van Nieuwstadt et
al., 1996). Macrophages were maintained as described
previously (Wensvoort et al., 1991). BHK-21 cells were
maintained in Glasgow minimal essential medium
(GIBCO BRL/Life Technologies Ltd.), according to the
method of Liljestro¨m and Garoff (1993).
Antisera
The production and characterization of the mAbs
122.17 and 126.9 directed against the N protein of LV
have been described by van Nieuwstadt et al. (1996). In
addition to these, seven other N-specific mAbs were
generated from mice immunized with purified LV virions
(van Nieuwstadt et al., 1996) and are listed in Table 1.
The hybridomas producing these mAbs were derived
from six consecutive fusion experiments: (I) mAb 122.17,
(II) mAb 125.1, (III) mAbs 126.9 and 126.15, (IV) mAbs 130.2
and 130.4, (V) mAbs 131.7 and 131.9, and (VI) mAb 138.22.
mAbs WBE1, WBE4, WBE5, and WBE6, which recognize
the N protein of European but not that of North American
TABLE 3
Sequence of Primers Used in PCR to Clone Wild-Type and Chimeric ORF7 Genes
Name Sequencea
Incorporated
restriction site
LV98 59-CCAGCAACCTAGGGGAGGACAGGCCAAAAAGAAAAAGCAGCCGAAGCTACATTTTCCCATGGCTGGTCCATCTGAC-39 EcoNI
LV99 59-CGTCTGGATCGATTGCAAGCAGAGGGAGCGTTCAGTCTGGGTGAGGACGTGCCGGAGGTCAGATGGACCAGCC-39 ClaI
LV101 59-GCTTGCAGGCGCCCGTGACGCTTTTCAATCAAGGCGGAGGACAGGCGTCGCTTTCATCCA-39 NarI
LV102 59-ATGTCCCGGGCTAAGCGGCGGAGGAATTAGCAGAAGCGTTAATCAGGCGCTGTGTAGCAGCAACCGGCAG-39 SmaI
LV108 59-GGAGTGGTTAACCTCGTCAAGTATGGCCGGTAAAAACCAGAGCC-39 HpaI
LV112 59-CCATTCACCTGACTGTTTAATTAACTTGCACCCTGA-39 PacI
LV134 59-TGGGGAATGGCCAGCCAGTCAATGACCTGTGCCGGATGTTTGGTGCAATGATAAAGTCC-39 MscI
a Nucleotides in italics indicate the restriction sites. The mutations with respect to the LV ORF7 sequence are underlined.
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isolates of PRRSV (Drew et al., 1995) were kindly pro-
vided by T. Drew (New Haw, U.K.). mAbs SDOW17, NS95,
and NS99 recognize the N protein of both European and
North American isolates of PRRSV (Nelson et al., 1993,
1996) and were a gift of D. Benfield (Brookings, U.S.A.).
mAb competition
The N-specific monoclonal antibodies were purified
from the culture medium of the hybridoma cells using
Protein G–Sepharose 4 Fast Flow (Pharmacia) according
to the protocol of the manufacturer. The purified IgG was
conjugated to HRPO using a modification of the method
of Wilson and Nakane (1978). The conjugated mAbs
were diluted to a final concentration of 4 mg/ml. Com-
petitive assays were made using these reagents in
(IPMA) to detect blocking of the binding of the HRPO-
conjugated mAbs by homologous and heterologous na-
tive mAbs. Macrophages were infected in M96 plates
with LV at an m.o.i. of 0.1. At 24 h after infection, plates
were fixed as described previously (Wensvoort et al.,
1986) and were incubated with the native mAb at con-
centrations of 100, 10, and 1 mg/ml in 0.5 M NaCl, 0.05%
Tween 80, and 4% horse serum for 1 h at 37°C. Then, the
conjugated mAb was added at concentrations that gave
optimal staining: 2 mg/ml (mAb 122.17, WBE5), 4 mg/ml
(mAbs WBE1, WBE4, and WBE6), or 16 mg/ml (mAbs 125.1,
126.9, 126.15, 130.2, 130.4, 131.7, 131.9, 138.22, SDOW17)
in 0.5 M NaCl, 0.05% Tween 80, and 4% horse serum.
After incubation for 1 h at 37°C, cells were washed with
0.15 M NaCl and 0.5% Tween 80 and stained with 3-
amino-9-ethyl-carbazole, as described by Wensvoort
et al. (1986).
Epitope mapping by pepscan
A complete set of solid-phase overlapping dodeca-
peptides was synthesized covering the amino acid se-
quence of the N protein of LV (128 residues; Meulenberg
et al., 1993). The synthesis of solid-phase peptides on
polyethylene rods and immunoscreening with an ELISA
type of analysis were carried out according to estab-
lished pepscan procedures (Geysen et al., 1984). The
monoclonal antibodies were tested at various concen-
trations containing 0.3–200 mg of IgG/ml. Peptides were
considered to represent antigenic sites if individual ab-
sorbance signals of two or more neighboring peptides
reproducibly reached a value of more than twice the
background. Background is defined as the average ab-
sorbance value of 20 consecutive low signals with a
variation coefficient of #20%.
Plasmid constructions
Two oligonucleotides located upstream (LV108) and
downstream (LV112) of ORF7 were used to amplify and
clone the ORF7 gene in pGEM-T, resulting in pABV431.
The sequences and positions of these and other oligo-
nucleotides used to amplify fragments of ORF7 are listed
in Table 1. In addition, four different chimeric constructs
were made by PCR-directed mutagenesis. The se-
quences coding for amino acids 25 and 28–30 (site B;
Fig. 3) were substituted for the corresponding sequences
of the EAV N protein. This was accomplished by PCR
amplification of ORF7 with LV134 and LV112. The mu-
tated DNA fragment was introduced in pABV431 using
the MscI and PacI site, which resulted in pABV455. The
region of ORF7 encoding amino acids 51–67 was substi-
tuted for the corresponding region of LDV ORF7.
pABV431 was digested with EcoNI and ClaI and ligated
to a PCR fragment produced with primers LV98 and LV99
digested with the same enzymes. This plasmid was
designated pABV463. The region of ORF7 encoding
amino acids 80–90 was substituted for the correspond-
ing region of the LDV ORF7 gene. The ORF7 gene of LV
was mutated in a PCR with primers LV101 and LV112. The
obtained fragment was digested with NarI and PacI and
ligated to pABV431 digested with ClaI and PacI. This
resulted in pABV453. Finally, the region encoding the
C-terminal part of the N protein (amino acids 111–128)
was replaced for a sequence encoding the correspond-
ing amino acids of the N protein of LDV. The ORF7 gene
was amplified with primers LV108 and LV102 and cloned
in the pGEM-T vector, which resulted in pABV456. The
wild-type and mutated ORF7 genes were excised from
pABV431, pABV453, pABV455, and pABV463 by digestion
with PacI (blunt ended) and HpaI and from pABV456 by
digestion with HpaI and SmaI. These genes were sub-
sequently inserted in the dephosphorylated SmaI site of
Semliki Forest virus expression vector pSFV1 (Liljestro¨m
and Garoff, 1991). Plasmids pABV470, pABV460,
pABV462, pABV518, and pABV471 containing the respec-
tive ORF7 genes in the correct orientation were further
tested for expression of the N protein.
In vitro transcription and transfection of Semliki
Forest virus ORF7 RNA
The pSFV1 plasmids containing different ORF7 con-
structs were linearized by digestion with SpeI and tran-
scribed in vitro, according to the protocol of Liljestro¨m
and Garoff (1993). The synthesized RNA was transfected
to BHK-21 cells in 15-mm wells of 24-well plates with
lipofectin as described by Liljestro¨m and Garoff (1993). At
24 h after transfection, cells were fixed with ice-cold 4%
(v/v) paraformaldehyde, and the N protein expressed by
the various ORF7 constructs was stained with mAbs in
the IPMA, essentially as described by Wensvoort et al.
(1986).
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